TopoTarget Present New Clinical Results with belinostat at the 33rd ESMO Congress and the 7th Biennial Ovarian Cancer Research Symposium


TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Cpenhagen 
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

TopoTarget Present New Clinical Results with belinostat at the 33rd ESMO
Congress and the 7th Biennial Ovarian Cancer Research Symposium 
			
Copenhagen, 9 July 2008 - TopoTarget A/S (CSE: TOPO) announced that preliminary
clinical data on belinostat, a histone deacetylase (HDAC) inhibitor being
investigated for the treatment of cancer, will be presented at two upcoming
medical meetings:   The 7th Biennial Ovarian Cancer Research Symposium which is
being hosted in Seattle, Washington, September 4-5, 2008 and the 33rd ESMO
congress, which is being hosted in Stockholm, Sweden, September 12-16, 2008. 

7th Biennial Ovarian Cancer Research Symposium

-	An oral presentation entitled, “Updated results from a phase II multicenter
trial of the histone deacetylase inhibitor (HDACi) belinostat, carboplatin and
paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer
(EOC)”, will be made during the symposium entitled “Novel Therapeutics and
Clinical Trials” on Friday, September 5, 2008 from 10.45 - 11.45 a.m. 


33rd ESMO Congress

-	A poster discussion entitled, “Phase (Ph) I/II study of the histone
deacetylase inhibitor belinostat (Bel) in combination with carboplatin (Ca) and
paclitaxel (P) in advanced solid tumors (Ph I) and relapsed ovarian cancer (Ph
II)” will be made during the session entitled “Developmental Therapeutics” on
Sunday, September 14, 2008 from 12.30 - 13.30 p.m. in auditorium K11. 




TopoTarget A/S


For further information, please contact:

Ulla Hald Buhl 	
Director IR & Communications	Mobile	+45 21 70 10 49







Background information

About Belinostat
Belinostat is a promising small molecule HDAC inhibitor being investigated for
its role in the treatment of a wide range of solid tumors and hematologic
malignancies either as a single-agent, or in combination with other active
anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid,
azacitidine and Velcade® (bortezomib) for injection.  HDAC inhibitors represent
a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes,
and have been shown to arrest growth of cancer cells (including drug resistant
subtypes); induce apoptosis, or programmed cell death; promote differentiation;
inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance
when used in combination with other anti-cancer agents. 
Intravenous belinostat is currently being evaluated in multiple clinical trials
as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell
lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal,
and ovarian cancers, either alone or in combination with anti- cancer
therapies.  An oral formulation of belinostat is also being evaluated in a
Phase I clinical trial for patients with advanced solid tumors. Several trials
in the belinostat program are conducted under a Clinical Trail Agreement (CTA)
under which the NCI sponsors clinical trials to investigate belinostat for the
treatment of various cancers, both as a single-agent and in combination
chemotherapy regimens.  In May 2005, TopoTarget announced the signing of a
Cooperative Research and Development Agreement (CRADA) with the NCI to conduct
preclinical and nonclinical studies on belinostat in order to better understand
its anti-tumor activity and to provide supporting information for clinical
trials. 

About TopoTarget 
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company is founded and run by clinical cancer specialists
and combines years of hands-on clinical experience with in-depth understanding
of the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and
topoisomerase II inhibitors). TopoTarget has a broad cllinical pipeline with 9
products in development, including belinostat which has shown proof of concept
as monotherapy in treating haematological malignancies and positive results in
solid tumours where it can be used in combination with full doses of
chemotherapy. The company's first marketed product Savene®/Totect® was approved
by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget's own sales
force in Europe and the US. For more information, please refer to
www.topotarget.com. 


TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law. 

Attachments

microsoft word - investor news no. 06-08 esmo biennial ovarian cancer research symposium 9 july 2008.pdf